Please login to the form below

Not currently logged in
Email:
Password:

Neurocrine Biosciences

This page shows the latest Neurocrine Biosciences news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s uterine fibroids drug aces second phase III trial

AbbVie’s uterine fibroids drug aces second phase III trial

AbbVie and Neurocrine Biosciences have a second positive phase III trial in hand for their uterine fibroids drug elagolix - setting up another regulatory filing for the drug. ... AbbVie in-licensed the drug from Neurocrine in 2010 for $575 million.

Latest news

  • FDA clears Teva's tardive dyskinesia drug Austedo FDA clears Teva's tardive dyskinesia drug Austedo

    FDA clears Teva's tardive dyskinesia drug Austedo. The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza. ... Now, the Israeli company can compete toe-to-toe with Neurocrine Biosciences' recently approved Ingrezza (valbenazine), which

  • Neurocrine bags FDA approval for first tardive dyskinesia drug Neurocrine bags FDA approval for first tardive dyskinesia drug

    Neurocrine bags FDA approval for first tardive dyskinesia drug. Ingrezza edges ahead of Teva’s rival drug Austedo. ... Neurocrine Biosciences has claimed the distinction of getting the first-ever FDA approval for a drug to treat tardive dyskinesia, a

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    The company's main rival in the race to bring a TD drug to market is Neurocrine Biosciences, which has a VMAT2 inhibitor codenamed NBI-98854 in phase III testing.

  • Neurocrine plans movement disorder drug filing in 2016 Neurocrine plans movement disorder drug filing in 2016

    Neurocrine plans movement disorder drug filing in 2016. NBI-98854 in trials for tardive dyskinesia. ... Neurocrine Biosciences saw its share rise steeply yesterday after it reported positive results for a movement disorder drug that has been tipped as a

  • Abbott christens new pharma company AbbVie

    It will start life with four projects in phase III, including gonadotropin-releasing hormone (GnRH) antagonist elagolix, partnered with Neurocrine Biosciences and in testing for endometriosis, as well as bardoxolone for

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics